½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1575346

¼¼°èÀÇ ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çü, Åõ¾àÇü, ÃÖÁ¾ »ç¿ëÀÚ, À¯Åë ä³Îº° ¿¹Ãø(2025-2030³â)

Dry Eye Medication Market by Drug Type (Over-The-Counter Drugs, Prescription Drugs), Dosage Form (Eye Drops, Gels, Ointments), End-User, Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 29¾ï 6,000¸¸ ´Þ·¯·Î, 2024³â¿¡´Â 32¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 7.22%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 48¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå¿¡´Â ´«¹°ÀÇ ºÎÁ·°ú ÁúÀÌ ³ª»Û °ÍÀ» Ư¡À¸·Î ÇÏ´Â ¾È±¸°ÇÁ¶Áõ ÁõÈıºÀÇ Áõ»ó ¿ÏÈ­¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ÀǾàÇ°ÀÌ Æ÷ÇԵ˴ϴÙ. ¿©±â¿¡´Â Àΰø´«¹°, Ç׿°ÁõÁ¦, ½ºÅ×·ÎÀ̵å Á¡¾ÈÁ¦, ½ÃŬ·Î½ºÆ÷¸° ¹× ¸®ÇÇÅױ׶ó½ºÆ® µîÀÇ Ã³¹æ¾àÀÌ Æ÷ÇԵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á°¡ ¿ä±¸µÇ´Â ¹è°æ¿¡´Â ½ºÅ©¸° »ç¿ë ½Ã°£ Áõ°¡, Àα¸ÀÇ ³ë·ÉÈ­, ¿¡¾îÄÁÀÇ º¸±Þ µîÀÇ ¿äÀÎÀÌ ÀÖ¾î, ¼¼°èÀûÀ¸·Î ¾È±¸°ÇÁ¶Áõ ȯÀÚ°¡ ±ÞÁõÇÏ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ëµµ´Â Áõ»óÀÇ ¿ÏÈ­¿Í ´«¹°ÀÇ »ý¼º°ú Ç°ÁúÀ» °³¼±ÇϱâÀ§ÇÑ ±Ùº»ÀûÀÎ ¿°ÁõÀÇ Ä¡·áÀÔ´Ï´Ù. ¸¸¼º ¾È±¸°ÇÁ¶Áõ, ƯÈ÷ ³ëÀΰú ÄÜÅÃÆ®·»Áî »ç¿ëÀÚ¸¦ ´ë»óÀ¸·Î º´¿ø, Ŭ¸®´Ð, ¼Ò¸Å ¾à±¹ µî ÃÖÁ¾ ¿ëµµ´Â ´Ù¾çÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 29¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 32¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 48¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 7.22%

½ÃÀå ¼ºÀåÀº Á¦¾à ¿¬±¸ÀÇ Áøº¸¿Í ´« °Ç°­¿¡ ´ëÇÑ ÀÏ¹Ý ½Ã¹ÎÀÇ ÀÇ½Ä Áõ°¡¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÃֽŠºñÁî´Ï½º ±âȸ·Î´Â º¸´Ù ±¸Ã¼ÀûÀÎ Ä¡·á¹ý °³¹ß, ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ý, Áø´Ü ¹× Ä¡·á °³º°È­¿¡¼­ AI ±â¼úÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù. ±â¾÷Àº ½Å±Ô Á¦Á¦ÀÇ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÏ°í ȯÀÚ Âü¿©¸¦ À§ÇÑ µðÁöÅÐ Çコ Ç÷§ÆûÀÇ È°¿ëÀ» ÅëÇØ ÀÌ·¯ÇÑ ±âȸ¸¦ È°¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ÀǾàÇ°ÀÇ ÀáÀçÀûÀÎ ºÎÀÛ¿ë, Á¦³×¸¯ ÀǾàÇ°°úÀÇ ³ôÀº °æÀï µîÀÇ ¿äÀο¡ ÀÇÇØ Á¦¾àÀ» ¹Þ°í ¼öÀͼºÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ °úÁ¦¸¦ ±Øº¹Çϱâ À§Çؼ­´Â À¯ÀüÀÚ Ä¡·á, ½Å±Ô »ý¹° Á¦Á¦, È¿´É°ú ȯÀÚÀÇ º¹¾à Áؼö¸¦ ³ôÀÌ´Â ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³·® µî ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ Áøº¸°¡ Çõ½Å ºÐ¾ß¿¡ Æ÷Ç﵃ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¶ÇÇÑ ¼±±¸ÀûÀÎ Ä¡·á¹ýÀÇ °øµ¿ °³¹ßÀ» À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½Ê°ú °øµ¿ ¿¬±¸ÀÇ ±¸Ãà¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. ½ÃÀå °æÀï ±¸µµ¸¦ »ìÆ캸¸é ÁøÈ­Çϴ ȯÀÚÀÇ ¿ä±¸¸¦ ÃæÁ·½ÃÅ°±â À§Çؼ­´Â ¹Îø¼º°ú Áö¼ÓÀûÀÎ Çõ½ÅÀÌ ÇÊ¿äÇÏ´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¾È±¸°ÇÁ¶ÁõÀ» º¸´Ù Á¾ÇÕÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ ±âÁ¸ÀÇ ¾à¹°¿ä¹ý¿¡ »ýÈ°½À°ü°ú ½Ä»ç °³ÀÔÀ» Á¶ÇÕÇÑ È¦¸®½ºÆ½ÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â µî µ¶ÀÚÀûÀÎ °¡Ä¡Á¦¾È¿¡ ÀÇÇÑ Â÷º°È­¸¦ ¸ñÇ¥·Î ÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® Çظí

¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆľÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ÇコÄɾÀÎÇÁ¶ó¿Í ÀǾàÇ° ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ È®´ë
    • Æó°æ ÈÄ ¿©¼º¿¡ À־ÀÇ ¾È±¸°ÇÁ¶ÁõÀÇ ÀÌȯÀ²ÀÇ »ó½Â
    • ¶óÀÌÇÁ ½ºÅ¸ÀÏ º¯È­¿Í ´« °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâ
    • ¾È°ú ÀÇ·á¿¡ÀÇ ¾×¼¼½º¸¦ Çâ»ó½ÃÅ°´Â ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ È®´ë
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • »õ·Î¿î ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â¼úÀÇ ¿¬±¸ °³¹ß ºñ¿ëÀÇ ³ôÀÌ°¡ ½ÃÀå ¼ºÀå¿¡ ¿µÇâ
    • ¸¸¼º ¾È±¸°ÇÁ¶Áõ Áõ»óÀ» È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ Ã³¹æ ¿ä°Ç¿¡ °üÇÑ È¯ÀÚÀÇ ¾îµåÈ÷¾î·±½ºÀÇ ¹®Á¦
  • ½ÃÀå ±âȸ
    • ¾È±¸°ÇÁ¶Áõ Ä¡·á¿¡ÀÇ ¾×¼¼½º¸¦ ¿ëÀÌÇÏ°Ô ÇÏ´Â ¿ø°Ý ÀÇ·á¿Í °¡»ó ÁøÂûÀÇ È®´ë
    • Çõ½ÅÀûÀÎ ¾È±¸°ÇÁ¶Áõ Ä¡·á³ª ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
    • °³º° ȯÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ÇÑ ¾È±¸°ÇÁ¶Áõ Ä¡·á ¼Ö·ç¼ÇÀÇ Ä¿½ºÅ͸¶ÀÌ¡À¸·Î À̾îÁö´Â ¸ÂÃãÇü ÀÇ·á µ¿Çâ Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ´Ù¾çÇÑ È¯ÀÚÃþ¿¡ ¸ÂÃá Ä¡·á ¼Ö·ç¼ÇÀÇ ºÎÁ·
    • ¾È±¸°ÇÁ¶ÁõÀÇ ÀÎÁöµµÀÇ ³·À½°ú Áø´ÜÀÇ Áö¿¬ÀÌ ½ÃÀå ¼ºÀåÀÇ °¡´É¼º¿¡ ¿µÇâ

Porter's Five Forces: ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Force Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡ÇÏ°í Àü·«Àû ±âȸ¸¦ Ž±¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» È°¿ëÇÏ°í, ¾àÁ¡À» ÇØ°áÇÏ°í, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆľÇ

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾È±¸ °ÇÁ¶ Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå °æÀï ±¸µµ ÆľÇ

¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®ÇÏ°í Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆľÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ È°¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D È°µ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇÏ°í ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ÇコÄɾî ÀÎÇÁ¶ó¿Í ÀǾàÇ° Á¶»ç¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
      • Æó°æ ÈÄ ¿©¼ºÀÇ ¾È±¸°ÇÁ¶Áõ ¹ßº´·üÀÌ ³ô´Ù
      • ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­ÀÇ Ã¤¿ë°ú ´«ÀÇ °Ç°­¿¡ ´ëÇÑ ¿µÇâ
      • ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ È®´ë¿¡ ÀÇÇØ ¾È°ú ÀÇ·á¿¡ÀÇ ¾×¼¼½º°¡ Çâ»ó
    • ¾ïÁ¦¿äÀÎ
      • ¾È±¸°ÇÁ¶Áõ Ä¡·áÀÇ ½Å±â¼úÀÇ ¿¬±¸ °³¹ß ºñ¿ëÀÇ ³ôÀÌ°¡ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâ
      • ¸¸¼º ¾È±¸°ÇÁ¶ÁõÀÇ È¿°úÀûÀÎ °ü¸®¸¦ À§ÇÑ Ã³¹æÀü ¿ä°Ç¿¡ °üÇÑ È¯ÀÚÀÇ ÁؼöÀÇ ¹®Á¦
    • ±âȸ
      • ¿ø°Ý ÀÇ·á¿Í °¡»ó °Ç°­ »ó´ãÀÇ È®´ë¿¡ ÀÇÇØ ¾È±¸°ÇÁ¶Áõ Ä¡·á¿¡ÀÇ ¾×¼¼½º°¡ ¿ëÀÌÇØÁø´Ù
      • Çõ½ÅÀûÀÎ ¾È±¸°ÇÁ¶Áõ Ä¡·á¹ý°ú ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
      • °³ÀÎÈ­µÈ ÀÇ·á Ãß¼¼°¡ Áõ°¡ÇÏ°í, °³º° ȯÀÚÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ¸ÂÃãÇü ¾È±¸°ÇÁ¶Áõ Ä¡·á ¼Ö·ç¼ÇÀÌ Á¦°øµË´Ï´Ù.
    • °úÁ¦
      • ´Ù¾çÇÑ È¯ÀÚÃþ¿¡ ¸ÂÃá Ä¡·á ¼Ö·ç¼ÇÀÇ ºÎÁ· ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå
      • ¾È±¸°ÇÁ¶ÁõÀÇ Áõ»ó¿¡ ´ëÇÑ ÀνÄÀÇ ³·À½°ú Áø´ÜÀÇ Áö¿¬ÀÌ ½ÃÀåÀÇ ¼ºÀå °¡´É¼º¿¡ ¿µÇâ
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »ç±³
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå : ¾à À¯Çüº°

  • ½ÃÆǾà
  • ó¹æ¾à

Á¦7Àå ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå : Á¦Çüº°

  • ¾È¾à
  • Á©
  • ¿¬°í

Á¦8Àå ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Ŭ¸®´Ð
  • ȨÄɾî
  • º´¿ø

Á¦9Àå ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍÅ°
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È
JHS 24.10.30

The Dry Eye Medication Market was valued at USD 2.96 billion in 2023, expected to reach USD 3.21 billion in 2024, and is projected to grow at a CAGR of 7.22%, to USD 4.83 billion by 2030.

The scope of the dry eye medication market encompasses pharmaceutical products aimed at alleviating the symptoms of dry eye syndrome, a condition characterized by insufficient or poor-quality tears. This often includes artificial tears, anti-inflammatory drugs, steroidal eye drops, and prescription medications like cyclosporine and lifitegrast. The necessity for these treatments is driven by factors like increased screen time, aging populations, and pervasive air conditioning use, leading to an upsurge in dry eye cases globally. Applications primarily focus on symptom relief and treating underlying inflammation to improve tear production and quality. End-use segments are broad, including hospitals, clinics, and retail pharmacies, targeting individuals with chronic dry eye, especially prevalent among older adults and contact lens users.

KEY MARKET STATISTICS
Base Year [2023] USD 2.96 billion
Estimated Year [2024] USD 3.21 billion
Forecast Year [2030] USD 4.83 billion
CAGR (%) 7.22%

Market growth is positively influenced by advancements in pharmaceutical research and increasing public awareness of ocular health. The latest opportunities include the development of more targeted therapies, personalized medicine approaches, and the integration of AI technologies in diagnosing and personalizing treatments. Companies can capitalize on these opportunities through investment in R&D for novel drug formulations and leveraging digital health platforms for patient engagement. However, market growth is constrained by factors such as stringent regulatory approvals, potential side effects of medications, and high competition from generic products, which could limit profitability.

To surmount these challenges, innovation areas could involve biotechnological advancements such as gene therapy, novel biologics, and improvement of drug delivery systems to enhance efficacy and patient adherence. Businesses should also focus on creating strategic partnerships and collaborations for the co-development of pioneering treatments. Insights into the market reveal a competitive landscape that demands agility and continuous innovation to cater to evolving patient needs. Companies should aim to differentiate through unique value propositions, such as offering holistic solutions that merge traditional medications with lifestyle and dietary interventions to manage dry eye more comprehensively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dry Eye Medication Market

The Dry Eye Medication Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing investment in healthcare infrastructure and pharmaceutical research
    • Higher incidence rates of dry eye conditions in post-menopausal women
    • Adoption of lifestyle changes and its impact on eye health
    • Expansion of telemedicine services facilitating better access to eye care
  • Market Restraints
    • High cost of research and development for new dry eye treatment technologies impacting market growth
    • Patient adherence issues with prescription requirements for effective management of chronic dry eye conditions
  • Market Opportunities
    • Expansion of telemedicine and virtual health consultations facilitating easier access to dry eye treatments
    • Rising investments in research and development for innovative dry eye therapies and drug delivery systems
    • Growing trend of personalized medicine leading to customized dry eye treatment solutions based on individual patient profiles
  • Market Challenges
    • Shortage of tailored therapeutic solutions for diverse patient demographics in the dry eye medication market
    • Limited awareness and delayed diagnosis of dry eye conditions affecting market growth potential

Porter's Five Forces: A Strategic Tool for Navigating the Dry Eye Medication Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dry Eye Medication Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dry Eye Medication Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dry Eye Medication Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dry Eye Medication Market

A detailed market share analysis in the Dry Eye Medication Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dry Eye Medication Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dry Eye Medication Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dry Eye Medication Market

A strategic analysis of the Dry Eye Medication Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dry Eye Medication Market, highlighting leading vendors and their innovative profiles. These include Aerie Pharmaceuticals, Inc., Alcon Inc., Aldeyra Therapeutics, Inc., Allergan plc, Bausch Health Companies Inc., Eyepoint Pharmaceuticals, Inc., Harrow Health, Inc., Johnson & Johnson Vision, Kala Pharmaceuticals, Inc., Mitotech S.A., Nicox S.A., Novartis International AG, Ocugen, Inc., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Pfizer Inc., Regenera Pharma Ltd., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., and Tarsus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Dry Eye Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Over-The-Counter Drugs and Prescription Drugs.
  • Based on Dosage Form, market is studied across Eye Drops, Gels, and Ointments.
  • Based on End-User, market is studied across Clinics, Home Care, and Hospitals.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing investment in healthcare infrastructure and pharmaceutical research
      • 5.1.1.2. Higher incidence rates of dry eye conditions in post-menopausal women
      • 5.1.1.3. Adoption of lifestyle changes and its impact on eye health
      • 5.1.1.4. Expansion of telemedicine services facilitating better access to eye care
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of research and development for new dry eye treatment technologies impacting market growth
      • 5.1.2.2. Patient adherence issues with prescription requirements for effective management of chronic dry eye conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of telemedicine and virtual health consultations facilitating easier access to dry eye treatments
      • 5.1.3.2. Rising investments in research and development for innovative dry eye therapies and drug delivery systems
      • 5.1.3.3. Growing trend of personalized medicine leading to customized dry eye treatment solutions based on individual patient profiles
    • 5.1.4. Challenges
      • 5.1.4.1. Shortage of tailored therapeutic solutions for diverse patient demographics in the dry eye medication market
      • 5.1.4.2. Limited awareness and delayed diagnosis of dry eye conditions affecting market growth potential
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dry Eye Medication Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Over-The-Counter Drugs
  • 6.3. Prescription Drugs

7. Dry Eye Medication Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Eye Drops
  • 7.3. Gels
  • 7.4. Ointments

8. Dry Eye Medication Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Home Care
  • 8.4. Hospitals

9. Dry Eye Medication Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Dry Eye Medication Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dry Eye Medication Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dry Eye Medication Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aerie Pharmaceuticals, Inc.
  • 2. Alcon Inc.
  • 3. Aldeyra Therapeutics, Inc.
  • 4. Allergan plc
  • 5. Bausch Health Companies Inc.
  • 6. Eyepoint Pharmaceuticals, Inc.
  • 7. Harrow Health, Inc.
  • 8. Johnson & Johnson Vision
  • 9. Kala Pharmaceuticals, Inc.
  • 10. Mitotech S.A.
  • 11. Nicox S.A.
  • 12. Novartis International AG
  • 13. Ocugen, Inc.
  • 14. Otsuka Pharmaceutical Co., Ltd.
  • 15. Oyster Point Pharma, Inc.
  • 16. Pfizer Inc.
  • 17. Regenera Pharma Ltd.
  • 18. Santen Pharmaceutical Co., Ltd.
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Tarsus Pharmaceuticals, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦